219 related articles for article (PubMed ID: 6771090)
1. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
Nilsson CG; Lähteenmäki P; Luukkainen T
Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
[TBL] [Abstract][Full Text] [Related]
2. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device.
Nilsson CG; Lähteenmäki P; Luukkainen T
Contraception; 1980 Feb; 21(2):155-64. PubMed ID: 6768490
[TBL] [Abstract][Full Text] [Related]
3. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
4. Sustained intrauterine release of levonorgestrel over five years.
Nilsson CG; Lahteenmaki PL; Luukkainen T; Robertson DN
Fertil Steril; 1986 Jun; 45(6):805-7. PubMed ID: 3086130
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
6. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
7. Hormonal evaluation of the intrauterine progesterone contraceptive system.
Bryand-Greenwood GD; Greenwood FC; Hale RW; Morishige WK
J Clin Endocrinol Metab; 1977 Apr; 44(4):721-7. PubMed ID: 849982
[TBL] [Abstract][Full Text] [Related]
8. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
10. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
11. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intra-uterine devices.
Nilsson CG; Lähteenmäki P; Robertson DN; Luukkainen T
Acta Endocrinol (Copenh); 1980 Mar; 93(3):380-4. PubMed ID: 7376797
[TBL] [Abstract][Full Text] [Related]
13. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
15. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the positive feedback of oestradiol during treatment with subcutaneous implants of d-norgestrel.
Weiner E; Johansson ED; Wide L
Contraception; 1976 Mar; 13(3):287-98. PubMed ID: 1248256
[TBL] [Abstract][Full Text] [Related]
17. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
18. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
20. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
